In human serum there are two protein fractions that are potent inhibitors to trypsin. These inhibitors travel with the a1-globulin and a2-globulin fractions when serum proteins are separated by electrophoresis (1-3). One ml of normal serum has sufficient amounts of trypsin inhibitor to neutralize the proteolytic effect of 1.15 (± 0.10) mg of crystalline trypsin. Approximately 90 per cent of the trypsin inhibitory proteins in serum migrate in the electrophoretic cell with the a1-globulin fraction, and the remainder with the a_2-globulin fraction (3).
In human serum there are two protein fractions that are potent inhibitors to trypsin. These inhibitors travel with the a1-globulin and a2-globulin fractions when serum proteins are separated by electrophoresis (1) (2) (3) . One ml of normal serum has sufficient amounts of trypsin inhibitor to neutralize the proteolytic effect of 1.15 (± 0.10) mg of crystalline trypsin. Approximately 90 per cent of the trypsin inhibitory proteins in serum migrate in the electrophoretic cell with the a1-globulin fraction, and the remainder with the a_2-globulin fraction (3) .
It is known that in many diseases of unrelated etiology the level of total serum trypsin inhibitor may be increased. This increase, therefore, is not specific for any disease, including acute pancreatitis. Also, it is likely that an increase in the a1-globulin trypsin inhibitor is no more specific in the various diseases than is a sedimentation rate. However, the results of a previous study indicate that in acute pancreatitis the a2-globulin inhibitor decreases, and in severe pancreatitis it frequently disappears. The divergent changes of the two serum globulin trypsin inhibitors in acute pancreatitis result in a marked increase in the ratio of the a,-to a2-globulin trypsin inhibitors. The decrease in the a2-globulin trypsin inhibitor in acute pancreatitis has been helpful in our laboratory in the diagnosis of acute pancreatitis (3) .
The determination of the serum a1,-and a2-globulin trypsin inhibitors involves the lengthy procedure of serum protein separation by electrophoresis, elution of protein fractions which involves many hours, and then the determination of the trypsin-inhibiting capacity of the protein fractions. The present complexities of this procedure make the determination difficult for the routine hospital laboratory. Because of these factors we * This work was supported by Grants 2A-5049 and A-4683 from the National Institute of Arthritis and Metabolic Diseases. sought methods that would permit an easier assay of the a2-globulin trypsin inhibitor. Many studies were made which included the determination of the inhibiting activities of the a,-and a2-globulin fractions to chymotrypsin, elastase, thrombin, plasmin, and collagenase. Although interesting data were obtained, these studies did not permit the differential assay of the serum a1-and a2-globulin trypsin inhibitors unless electrophoresis was done.
Continuing along this line of investigation, we determined that when trypsin was added to serum and the mixture subjected to electrophoresis, a substance with trypsin-like activity was detected, migrating with the a2-globulin fraction. This was an unexpected finding, since the serum to which trypsin was added contained sufficient trypsin inhibitor to completely neutralize many times the amount of trypsin added. Also, other known inhibitors of trypsin and plasmin failed to inhibit this activity.
The aims of this study were: 1) to investigate the properties of the substance with the trypsinlike activity that appears in the a2-globulin fraction when trypsin is added to serum (this substance is designated trypsin-protein esterase) ; and 2) to determine whether the addition of chymotrypsin to serum will produce a substance with proteolytic activity which migrates with the a2-globulin fraction (chymotrypsin-protein esterase).
METHODS AND MATERIALS
The following substances were used in this study: 1) Benzoyl-L-arginine-paranitroanilide (BAPNA), originally developed by Karmen, was synthesized as previously reported (4). 2) A supersaturated aqueous solution of BAPNA in a concentration of 1 mg per ml was prepared by heating to 85' C until dissolution was complete and then cooling in an ice bath. The solution may be stored at room temperature for at least 1 month without appreciable change. 3) 0.1 M Tris buffer, pH 7.67, 0.005 M in CaCl,; 0.005 M Tris buffer, 0.5 M in NaCl.
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PROTEIN BINDING OF PANCREATIC PROTEOLYTIC ENZYMES 4) Trypsin standards; lyophilized crystalline trypsin (Worthington Biochemical Corp.) was used. A stock standard of trypsin in a concentration of 1 mg per ml was prepared in 0.0025 N HCl. Working standard solutions of trypsin were prepared by diluting the stock standards to the desired concentration. Protein content of trypsin standards was determined by measuring at 280 mu in the Beckman DU spectrophotometer and using the conversion factor of 0.585 as described by Kunitz (5). 5) Chymotrypsin; lyophilized crystalline chymotroypsin (Worthington Biochemical Corp.) was used. 6) Casein substrate; 3 g of vitamin-free casein (Pfanstiehl) was suspended in 100 ml of Tris buffer adjusted to pH 7.6 with HCI. The suspension was heated in a boiling water bath for 15 minutes to dissolve the casein. The solution had a final pH of 7.0. 7) Veronal buffer, pH 8.6, 0.075 ionic strength. 8) Bromphenol blue dye; 0.10 g of dye and 50 g ZnSO4 H2O in 50 ml of glacial acetic acid were diluted to 1 L with water. 9) Paper strips; Whatman 3 MM, 3.0 cm wide X 30.6 cm long (Spinco, 300-028). 10) BAPNA substrate for spraying; a 400 mg per 100 ml solution was prepared by dissolving the substrate in a 1: 1 solution of dimethyl-formamide: Tris buffer. 11)
Partially purified a,-globulin trypsin inhibitor was prepared by a modification of the method described by Bundy and Mehl (6) . A diethylaminoethyl cellulose chromatographic column was used in place of Dowex-1. Alpha2-globulin trypsin inhibitor was prepared by ammonium sulfate precipitation and elution from a diethylaminoethyl cellulose column. The following methods were used: 1. Measurement of trypsin. 1) Trypsin digestion of casein was measured according to the method of Kunitz as modified by Bundy and Mehl (2) . 2) Esterase activity of trypsin was measured, with the TAMe substrate and the automatic titrator with titrographic recording (Copenhagen). To 1.0 ml of the substrate and 8.0 ml of buffer, incubated at 250 C, was added 1 ml of the enzyme dissolved in saline, or (Figure 1 ). 3) Activity of trypsin also was measured, with the synthetic substrate BAPNA (4) . Trypsin splits this substrate to yield benzoyl-L-arginine and the yellow dye, paranitroaniline. Trypsin activity in a 3.0-ml BAPNA system, measured in Beckman absorbance units per minute at 383 mu, is directly proportional to the amount of trypsin added. When the change in absorbance per minute is recorded, trypsin can be assayed accurately in the range of 0.5 to 1.0 jug. To increase the sensitivity, trypsin was incubated with BAPNA and buffer for 5 minutes or longer and the reaction stopped by the addition of 1 ml of 0.25 N HCL. The total increase in absorbance compared with blanks can accurately assay trypsin in the range of 0.25 jig ( Figure   2 4. Starch block electrophoretic separation of serum or mixtures of serum and enzyme. Four ml of serum or 4 ml of serum containing 3.36 mg of crystalline chymotrypsin was applied to starch blocks measuring 38 X 5 X 1 cm. The system was allowed to run for 25 to 30 hours at 50 C with 122 v across the block. Protein fractions were eluted from 1-cm sections with 10 ml of cold isotonic saline for 16 hours. The eluates were filtered and the protein content determined by measuring absorbance at 280 m~u in the Beckman DU spectrophotometer.
5. Trypsin inhibitor assay of serum protein fractions. 1) Paper electrophoresis; 0.8 ml of the eluate from each centimeter section (except in the a,-globulin region where high inhibitor levels permitted the use of smaller quantities) was incubated for 5 minutes with the trypsin standard; the residual trypsin then was assayed, with the BAPNA substrate. After a 10-minute incubation period the hydrolysis of the substrate was stopped by the addition of 1.0 ml of 0.25 N HCl and the absorbance recorded.
2) Starch block electrophoresis; 0.2 ml of starch block eluates (0.1 ml of fractions containing large amounts of inhibitor) was incubated with 20 jug of trypsin for 5 minutes at 370 C; residual trypsin then was assayed, with TAMe as the substrate in the automatic titrator.
6. Determination of trypsin-binding protein of serum. amounts of trypsin varying from 50 to 2,000 ug were added. The proteins in the mixture of trypsin and serum were separated by electrophoresis according to the procedure described in paragraph 3. Triplicate electrophoretic strips were made; one was stained with bromphenol blue for protein localization; another was sprayed with a solution of BAPNA in dimethylformamide and Tris buffer; the third was cut into 1-cm sections, the protein fractions eluted in Tris buffer for 16 hours, and the eluate assayed for tryptic or tryptic inhibitory activity. In addition, serum alone was electrophoresed, and trypsin followed by a2-globulin trypsin inhibitor was added to the eluates from the centimeter sections of electrophoretic paper strips of serum proteins. Alpha2-globulin trypsin inhibitor was added to aliquots of the same eluates and was followed by the addition of trypsin. This mixture was incubated with BAPNA for 80 minutes at 370 C and the reaction stopped by the addition of 1.0 ml of 0.25 N HCl. Absorbance units were read on the Beckman DU spectrophotometer at 383 mAt against a blank of buffer and substrate treated like the sample. A serum control was established by diluting serum to which no trypsin was added and treating it as was the sample. 2) Starch block electrophoretic fractions; 1 ml of the eluates of serum protein fractions was incubated with 40 ,ug of trypsin and 600 Atg of a1-globulin trypsin inhibitor. 40 ,Ml of serum (256 jMg per ml). The difference between the trypsin inhibitors in graphs A and B is 28.9 ug per 40 ul (720 ug per ml). In graph B the sum of the trypsin inhibited (720 ug per ml) and the tryptic activity measured in the a2-globulin zone (116 ug per ml) is 836 ug per ml of serum. It is apparent that this sum corresponds to the 800 jug of trypsin added to the 1 ml of serum. Graph C shows that the addition of 1,400 ug of trypsin to the serum did not increase the tryptic activity assayed in the a2-globulin zone.
The following results were obtained when trypsin, followed by partially purified a2-globulin trypsin inhibitor, was added to the protein eluates from the centimeter sections after electrophoresis of serum alone. a2-Globulin trypsin inhibitor was added in amounts sufficient to completely inhibit the added trypsin (Table I ). Trypsin-like activity was recorded only in the a2-globulin zone ( Figure  5 , graph A). When the a2-globulin trypsin inhibitor was added to the eluates and followed by the addition of trypsin, trypsin-like activity again was recorded only in the a2-globulin region, but approximately one-third less in amount (graph B).
Increasing amounts of trypsin (100 to 1,000 ug in increments of 100 jug) were added to 1 ml of normal serum. ( Figure 6 ). As more trypsin was added, no further substantial increase in tryptic activity was noted until the addition of 900 mg, at which point serum tryptic inhibitory activity was exceeded, and again increased tryptic activity was recorded.
The results illustrated in Figure 6 are representative of four similar studies. 2. Starch block electrophoresis. The following results were obtained when trypsin, followed by a,,-globulin trypsin inhibitor, was added to the serum protein eluates. Trypsin-like activity was seen only in the a2-globulin zone (Figure 7) . Sufficient a1-globulin trypsin inhibitor was added to neutralize 95 per cent of the added trypsin. It is noted, however, from Figure 7 that there was a large amount of normally occurring trypsin inhibitor in the a,2-globulin fraction, in addition to the added a,-globulin trypsin inhibitor. The amount of trypsin-like activity recovered from the a2-globulin zone was the equivalent of 92 Mug of crystalline trypsin for 0.4 ml of serum; 240.0 ug of trypsin had been added to the eluates of a,2-globulin fraction.
When the eluates from the mixture of serum and chymotrypsin were assayed for enzymatic activities on different substrates, the following results were obtained. 1) With ATEe as a substrate, chymotrypsin activity was noted only in the a2-globulin fraction (Figure 8 ). The amount of chymotrypsin activity recovered from the a2-globulin zone was the equivalent of 103 ug of crystalline chymotrypsin per 4 ml of serum; 3.36 mg of crystalline chymotrypsin was added to the 4 ml of serum prior to electrophoresis. 2) With casein as the substrate, once again enzymatic activity was noted only in the eluates from the a2-globulin zone (Figure 8 ). 3) With BAPNA and TAMe as the substrates, no enzymatic activity was detected in the a2-globulin fraction, nor in any of the other protein fractions (Figure 8) eluates of the chymotrypsin and serum mixture,
followed by the addition of 800 ,ug of a,-globulin trypsin inhibitor, no enzymatic activity was noted in any of the fractions using TAMe as the substrate. It is noted from Figure 9 that 800 Mug of the a1-globulin trypsin inhibitor is more than sufficient to neutralize 20 ,Mg of crystalline trypsin. It became important to determine whether known trypsin and plasmin inhibitors inhibit the trypsin-protein esterase activity found in the a2-globulin zone. Tryptic activity in the a2-globulin zone was obtained by two methods: by adding trypsin to serum in amounts less than the trypsininhibiting levels of the serum and by elution of the a2-globulin zone from electrophoretic strips containing the fractionated proteins of a mixture of trypsin and serum. It was demonstrated that neither the purified serum a,-nor the a2-globulin trypsin inhibitor suppressed the tryptic activity from either of the aforetnentioned sources (Table  I) . Soybean and colostrum trypsin inhibitors also did not inhibit the trypsin-protein esterase. DISCUSSION It is apparent that when trypsin or chymotrypsin is added to serum in an amount less than that necessary to saturate the inhibitors, proteolytic enzymatic activity is detected in the a2-globulin zone. The character of the activity is of interest, since it becomes important to determine whether the enzymatic activity is a result of the activation of a naturally occurring precursor substance in blood or is a result of the binding of the added enzyme to an a2-globulin protein with the complex retaining enzymatic activity.
Of the different proteolytic enzyme systems in blood, the activation of plasminogen to plasmin must be considered as a possibly responsible factor for the a2-globulin enzymatic activity when trypsin is added to serum. It is known that plasminogen activation can occur spontaneously by precipitation of the globulin fraction, by tissue activators, by urinary activators, by trypsin, and by plasmin. The reaction in each case involves liberation of a peptide moiety from plasminogen (7) (8) (9) . Several factors indicate, however, that the activation of plasminogen to plasmin is not responsible for the enzymatic activity in the a2-globulin fraction after addition of trypsin to serum. Norman has shown that the plasminogen in human plasma migrates with the ,8-globulin fraction upon electrophoresis in starch (10) . Studies in this report have demonstrated that the only fraction of human serum proteins that contains proteolytic or esterolytic activity when trypsin and a trypsin inhibitor are added is the a2-globulin fraction. Also, the enzymatic activity in the a2-globulin zone is not inhibited by the a2-globulin trypsin inhibitor or soybean trypsin inhibitor, both of which suppress plasmin. Another fact against the hypothesis of plasminogen activation is the observation that, when chymotrypsin is added to serum and the proteins of the mixture are separated by electrophoresis, enzymatic activity again is noted only in the a2-globulin zone. This activity will hydrolyze the chymotrypsin substrate N-acetyl-L-tyrosine-ethyl ester, but not trypsin or plasmin substrates (BAPNA or TAMe). Also, it will hydrolyze casein, which is a substrate for trypsin as well as chymotrypsin.
Another proteolytic enzyme present in serum, which must be considered in attempting to account for the enzymatic activity in the a2-globulin zone when trypsin is added to serum, is the esterase derived from the first component of complement. Donaldson (11) has shown that the extraction of serum with ether resulted in the separation of a fraction rich in esterase activity. The activity could not be identified with plasmin. The etheresterase digested synthetic amino acid esters simi-lar to those digested by esterase prepared from < partially purified preparation of the first corn ponent of complement (C'1-esterase). The substrates digested by both of these esterases include N-acetyl-L-tyrosine ethyl ester, N-acetyl-L-tryptophan ethyl ester, benzoyl-L-arginine ethyl ester, and p-toluene sulfonyl-L-arginine methyl ester. The properties of the ether-esterase suggest its identity with an esterase derived from the first component of complement (11) . Although the electrophoretic mobility of the ether-esterase on paper was similar to an a-globulin at pH 8.6 and ionic strength 0.15, it is unlikely that the etheresterase is identical with the trypsin or chymotrypsin protein esterase for the following reasons: 1) the trypsin-protein esterase digests casein but does not hydrolyze N-acetyl-L-tyrosine ethyl ester; 2) the chymotrypsin-protein esterase does not digest BAPNA or TAMe.
The more suitable explanation for the a2-globulin enzymatic activity is that trypsin or chymotrypsin can be bound to a component of the a2-globulin of serum. The fact that, when trypsin is added to serum, the sum of the inhibited trypsin plus the tryptic activity of the trypsin-protein esterase equals the amount of trypsin added, is further evidence favoring this hypothesis. The trypsin-a2-globulin complex retains its caseinolytic or esterolytic properties despite the fact that it migrates electrophoretically in the direction opposite to that of crystalline trypsin. However, the complex is not affected by the potent trypsin inhibitors found in soybean, colostrum, and in the a,-and a2-globulin fractions of human serum. The trypsin-a2-globulin complex is an active proteolytic enzyme with some properties different from crystalline trypsin. The type of combination that occurs between the trypsin and a2-globulin fraction that permits the complex to travel with the a2-globulin is not clear. It is logical to conclude, however, that the active tryptic site remains unmasked in the complex. With this in mind, the ineffectiveness of the usual trypsin inhibitors to the protein-bound trypsin, which can digest casein, is difficult to explain at present; it can only be stated that the complex has characteristics different from crystalline trypsin.
The properties of this protein-bound proteolytic enzyme may be a factor in explaining phenomena that previously have been enigmatic. Reports in a the literature have been concerned recently with "serum trypsin" levels in acute pancreatitis and pancreatic cancer (12, 13) . The substances that have been used for the measure of "serum trypsin" -for the most part have been benzoyl-L-arginine compounds. In addition to the fact that thrombin and plasmin hydrolyze these substrates, it is necessary to confirm the reported elevated "serum trypsin levels" in pancreatic disease by more precise methods. However, the fact that trypsin can be bound to an a2-globulin fraction and maintain its tryptic activity, which is unaffected by the serum inhibitors, presents a mechanism whereby serum may contain both tryptic activity and tryptic inhibitory activity simultaneously. The possibility that other proteolytic enzymes may be bound to proteins that occur in blood is of considerable interest. It has been established already, that chymotrypsin can be bound to an a2-globulin protein in a fashion similar to that of trypsin. The question naturally arises whether or not thrombin and plasmin (both of which are proteolytic enzymes resembling trypsin in many respects), ether-esterase, and chloroform-esterase have similar relationships with a serum globulin. The basic principles involved in the binding of trypsin become important in a consideration of the mechanism involved in acute pancreatitis. It is known that human pancreatic juice obtained by catheter drainage of the duct of Wirsung has no spontaneous tryptic activity (4) . It does, however, contain substantial amounts of trypsin inhibitor. Likewise, pancreatic tissue extracts contain substantial amounts of trypsin inhibitory substances. The etiology of pancreatitis remains obscure, but it is agreed by many that an important factor in this disease is the digestive action of the pancreatic proteolytic enzymes. The enzymes that are likely to be directly concerned with this action are trypsin and chymotrypsin. It appears that one of the keys to the production of pancreatitis is the transformation of trypsinogen to trypsin and that the newly formed trypsin be permitted by its chemical environment within the pancreas to maintain proteolytic activity. The binding of trypsin to a protein that is active in the presence of trypsin inhibitors presents a mechanism whereby small amounts of trypsin in or about the pancreas may break down tissue despite the presence of large amounts of substances inhibitory to trypsin.
